Search PubMed⌕ Search

Biomedical subjects

T R Bai

Publications and source records attributed to T R Bai.

At least 37 records · Page 2Linked to original sources
PubMed1995

Neuropeptide content of lungs from asthmatic and nonasthmatic patients.

Tracheal and lung parenchymal SP-LI (substance P-like immunoreactivity) and VIP-LI (vasoactive intestinal peptide-like immunoreactivity) content was measured in HPLC-purified tissue extracts from patients with and without asthma. We detected significantly less SP-LI in tracheal tissue from asthmatic than from nonasthmatic patients, whereas parenchymal SP-LI content was not significantly different between these groups. This finding does not support the concept that asthmatic lungs contain excessive amounts of SP. Indeed, lower SP-LI content of tracheal tissues from asthmatic patients may reflect augmented SP release followed by degradation. We detected greater quantities of VIP-LI in tracheal than in parenchymal tissue in both groups, but did not detect significant differences in VIP-LI content in tracheal or parenchymal tissues from asthmatic and nonasthmatic patients. These findings indicate that asthmatic and nonasthmatic lungs contain similar levels of VIP.

Adolescent↗
PubMed1995

Effect of chronic antigen and beta 2 agonist exposure on airway remodeling in guinea pigs.

We recently reported that chronic exposure to fenoterol (FEN) in guinea pigs increases in vivo and in vitro airway responsiveness to a degree similar to that induced by chronic antigen (ovalbumin [OA]) exposure. We hypothesized that these changes were due to airway inflammation and airway remodeling. To trace newly recruited granulocytes as a marker of inflammation and to detect DNA replication in resident airway wall cells, the nucleotide 5'-bromo-2'-deoxyuridine (BrdU) was administered intermittently over the six-wk period of chronic FEN and/or OA exposure. Noncartilaginous airway dimensions were measured and the area fraction of BrdU-immunoreactive and total nuclei in adventitia, smooth muscle, and epithelium was determined by immunohistochemistry and point counting. The proliferation index was defined as the ratio of the two area fractions in each wall area. The adventitial areas of FEN- and OA-treated airways were respectively 62 and 88% greater than those of control airways (p < 0.05). The inner wall areas were not increased. The smooth muscle cell and epithelial cell proliferation index was increased after OA (smooth muscle index: control, 2.7 +/- 1.1% [SEM]; OA, 23.0 +/- 3.7%; p < 0.02) but not after FEN exposure, and there was an increased number of BrdU-immunoreactive granulocytes in the adventitia and epithelium after OA but not after FEN exposure. The increased in vivo airways responsiveness produced by chronic OA or FEN exposure may be attributable to adventitial thickening and increased in vitro muscle contractility, but the cellular mechanisms underlying these and other airway wall responses are different.(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenergic beta-Agonists↗
PubMed1995

Glucocorticosteroid treatment of asthma.

Inhaled glucocorticoids are currently an important part of asthma management. There is no evidence that the more recently introduced inhaled agents, which have high topical activity and low systemic bioavailability, are unsafe at doses below 2000 micrograms/d. The choice of the delivery device for inhaled glucocorticosteroids is as important as the choice of the particular drug.

Asthma↗
PubMed1994

Transforming growth factor beta 1 gene expression in human airways.

BACKGROUND: Asthmatic airways have a characteristic deposition of connective tissue under the epithelial basement membrane, but the mediators involved in this alteration are unknown. Several authors have postulated that transforming growth factor beta 1 (TGF-beta 1) could be overexpressed in asthmatic airways. METHODS: Lung samples from 16 asthmatic patients, six patients with chronic obstructive pulmonary disease (COPD), and six non-obstructed smokers were analysed. RNA was extracted from these tissues to measure expression of TGF-beta 1 by Northern blot analysis using a cDNA probe for TGF-beta 1. The level of expression was quantitated by densitometry using glyceraldehyde 3-phosphate dehydrogenase mRNA as a control. TGF-beta 1 was localised to specific cell types in these lungs by immunohistochemical analysis using polyclonal antibodies specific for intracellular and extracellular TGF-beta 1. RESULTS: The 2.5 kb TGF-beta 1 mRNA was seen in all 18 samples analysed by Northern blotting and densitometric analysis showed no difference between the asthmatic group (mean (SD) 108% (43%)), the group with COPD (122% (33%)), and the non-obstructed group (100% (49%)). The TGF-beta 1 precursor was immunolocalised throughout the airway wall including the epithelium and in alveolar macrophages. The mature TGF-beta 1 was localised primarily within the connective tissue of the airway wall. These patterns of expression of both forms of TGF-beta 1 were similar in lungs from asthmatic patients, those with COPD, and controls. CONCLUSIONS: While TGF-beta 1 mRNA and protein are abundantly expressed in human lungs, there is no clear difference in expression between the airways of asthmatic subjects and those of smokers with and without COPD.

Adolescent↗
PubMed1994

Epithelial modulation of cholinergic responses in human tracheal smooth muscle.

The aim of this study was to test the hypothesis that the increase in maximal responses to histamine, acetylcholine, and cholinergic electrical field stimulation and decreased relaxant responses to isoprenaline reported in asthmatic tracheal smooth muscle result from the epithelial damage observed in asthma. The effect of mechanical removal of the epithelium on contractile and relaxant responses was examined in normal human postmortem tracheal smooth muscle strips. The epithelium was removed from alternate tracheal strips obtained from 25 subjects within 14 h of sudden death from nonrespiratory causes. In paired samples, contractile cholinergic and inhibitory nonadrenergic, noncholinergic (i-NANC) neural responses to electrical field stimulation and responses to exogenous histamine, potassium chloride, theophylline, and isoprenaline were unaffected by removal of the epithelium. However, the maximal isometric tension (Tmax) induced by methacholine increased by 70.1 +/- 19.8% (mean +/- SE, p < 0.005, n = 9), without alteration in EC50. These data suggest that disruption of the epithelium is unlikely to be the explanation of the abnormalities observed in trachea in fatal asthma. Explanations of the increase in maximal response to methacholine following removal of the epithelium include loss of an epithelium-derived relaxant factor released via an epithelial muscarinic receptor or loss of a specific permeability or metabolic barrier imposed by the epithelium for methacholine.

Acetylcholine↗
PubMed1994

Platelet-derived growth factor and its receptor in lungs from patients with asthma and chronic airflow obstruction.

The airway walls of patients who have asthma or chronic obstructive pulmonary disease (COPD) are thickened by an increase in the amount of smooth muscle and connective tissue. Platelet-derived growth factor (PDGF) is a candidate cytokine for this increase because it can produce smooth muscle proliferation in vitro. The present study was designed to examine the expression of PDGF and its receptor (PDGFR) in lungs from six asthmatics, six patients with COPD, and six patients with normal lung function. PDGF was immunolocalized to tissue macrophages, but the number of PDGF-positive cells was similar in all three groups. PDGFR-beta was rarely expressed on interstitial cells, and, occasionally, on bronchial epithelium. Northern blotting, performed on tissue from the same groups, showed a positive correlation of PDGF(B) with PDGFR-beta mRNA level (r = 0.74, P < 0.001) and a higher abundance of PDGF(B) and PDGFR-beta mRNA in the asthmatics vs. the COPD (P < 0.05). We conclude that PDGF and its receptor are expressed in human lungs but do not correlate closely with the structural changes in diseased airways.

Adolescent↗
PubMed1994

Chronic fenoterol exposure increases in vivo and in vitro airway responses in guinea pigs.

We tested the hypothesis that the regular inhalation of a beta 2-adrenergic receptor (beta 2AR) agonist increases airway responsiveness in guinea pigs. A potent beta 2AR agonist, fenoterol hydrobromide, in sublaryngeal doses equivalent to maximal doses used in the treatment of asthma on a weight basis (5.28 micrograms/kg), was administered by nebulizer three times a day for 6 weeks to normal adolescent guinea pigs (FEN, n = 10) and to ovalbuminsensitized guinea pigs challenged twice weekly with ovalbumin (OA + FEN, n = 20), although not in the 12 h prior to or 4 h after antigen challenge. Controls included saline-treated normal animals (CON, n = 10) and ovalbumin-sensitized animals treated with repeated antigen challenge and saline (OA, n = 20). At 72 h after the last administration of saline, fenoterol, and ovalbumin, the dose-response relationship between pulmonary resistance (RL) and nebulized acetylcholine (ACh) was measured. RLmax increased 2-fold and the ACh concentration causing a 10-fold increase in RL (PC10) decreased 4-fold in the FEN, OA, and OA + FEN groups as compared to the CON group. In the FEN, OA, and OA + FEN groups, in vitro tracheal smooth-muscle contractile responses to maximal concentrations of acetylcholine increased 2-fold, and this increase was not due to increased smooth-muscle mass. There was no evidence for beta 2AR desensitization as judged by in vitro tracheal smooth-muscle relaxant responses to fenoterol. These results suggest that chronic beta 2AR stimulation increases airway smooth-muscle contractility and in vivo airways responsiveness to a degree similar to that induced by chronic antigen exposure. A similar effect in human asthmatics may explain the adverse effects observed during prolonged treatment with these drugs.

Aerosols↗
PubMed1993

Effect of an inhibitor of nitric oxide synthase on neural relaxation of human bronchi.

This study examines the roles of peptides and nitric oxide (NO) as mediators of inhibitory nonadrenergic, noncholinergic (NANCi) neurons in human and guinea pig airways in vitro. Tissues were contracted with 0.3 microM methacholine (MCh) and relaxation studied before and after the addition of the peptidase alpha-chymotrypsin (alpha-CT) (2 U/ml) and NG-nitro-L-arginine methyl ester (L-NAME 0.1-1.1 mM), an inhibitor of NO synthase, the enzyme catalyzing the formation of NO. alpha-CT alone, in comparison to parallel time controls, inhibited control relaxation to electrical field stimulation (EFS) by 29.2 +/- 8.6% in guinea pig tracheae (n = 9), whereas a small augmentation of relaxation was observed in human bronchi (n = 7). L-NAME inhibited the NANCi response in both guinea pig tracheae and human bronchi: in guinea pig tracheae, maximal inhibition of the alpha-CT-insensitive relaxation was 59.3 +/- 11.5% (SE, P = 0.003) at low frequencies (4-16 Hz) and 28.6 +/- 8.9% (P = 0.08) at 32 Hz; in human bronchi, the maximal inhibition was 37.7 +/- 9.3% (P = 0.008) at 8 or 16 Hz, and 37.9 +/- 5.9% (P = 0.005) at 32 Hz. Inhibition was greater after repeated baseline EFS for 90 min before initiation of contraction with MCh and addition of L-NAME (59.8 +/- 13.9% after repeated baseline EFS, n = 4; vs. 34.9 +/- 6.2% without repeated baseline EFS, n = 9, P = 0.025). Relaxant responses to sodium nitroprusside, vasoactive intestinal peptide, and isoproterenol were not affected by L-NAME. L-Arginine (10 mM), a precursor of NO, partially reversed the effect of L-NAME.(ABSTRACT TRUNCATED AT 250 WORDS)

Amino Acid Oxidoreductases↗
PubMed1993

Airway smooth muscle shortening in excised canine lung lobes.

To estimate the importance of lung parenchymal airway interdependence in attenuating airway narrowing, airway smooth muscle shortening in response to nebulized carbachol was measured in excised canine lung lobes and compared with the calculated load applied by lung elastic recoil. Pulmonary resistance of matched right and left upper lobes of five dogs was measured in a pressure-compensated volume plethysmograph by forced oscillation (6 Hz) before and after administration of an aerosol of carbachol (250 mg/ml) or saline. Matched lobes were studied at transpulmonary pressures (PL) of 5, 7, 10, 12, and 15 cmH2O. The lungs were then fixed at that PL by pulmonary arterial perfusion with formaldehyde, and cross sections of multiple airways from each lobe (n = 275) were examined by use of morphometric techniques to measure luminal area and smooth muscle length. By use of the saline lobe as a control, percentage of muscle shortening and decrease in airway lumen area caused by carbachol could be calculated. Passive and active smooth muscle stresses in each airway were calculated from PL and the calculated change in peribronchial pressure for a given change in airway diameter. The increase in pulmonary resistance and average smooth muscle shortening after administration of carbachol was greater in lobes held at lower PL. There was marked variation in narrowing between airways within a lobe: smooth muscle shortening ranged between 0 and 65% but averaged < 45% at all levels of PL.(ABSTRACT TRUNCATED AT 250 WORDS)

Airway Resistance↗
PubMed1993

Small airways dimensions in asthma and in chronic obstructive pulmonary disease.

The purpose of this study was to compare the dimensions of the peripheral airways in fatal asthma with those from patients with nonfatal asthma, mild COPD, and normal lung function. Lung specimens from eight individuals who had fatal asthmatic attacks were obtained at postmortem and compared with similar specimens from three asthmatic patients who died of an unrelated cause and four specimens obtained from known asthmatic patients who required lung resection for tumor. These 15 asthmatic lungs were also compared with lungs resected for peripheral neoplasms from 15 patients with normal airway function (FEV1, % of predicted > 85) and 15 patients with mild chronic airflow obstruction (FEV1, % of predicted < 85). All membranous airways with a long-short diameter ratio of 3:1 or less were examined. The smooth muscle and the tissue areas external and internal to the muscle layer were traced using a Bioquant BQ System 4. The same system was used to evaluate the fraction of the submucosa and adventitia taken up by blood vessels. The adventitial, submucosal, and muscle area of the asthmatic airways were greater than those of COPD and control (p < 0.01), and the muscle area was greater in COPD than in control lungs (p < 0.05). These parameters were also greater in the 8 patients with fatal asthma compared with the 7 patients with nonfatal asthma (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1993

Expression of beta 2-adrenergic receptor mRNA in peripheral lung in asthma and chronic obstructive pulmonary disease.

Previous studies have indicated an increased number of beta 2-adrenergic receptors (beta 2AR) on bronchial smooth muscle in fatal asthma. This study evaluates the utility of autopsy lung for studies of gene expression and examines the hypothesis that increased expression of beta 2 AR mRNA in peripheral lung underlies the increased receptor number reported in central airways in fatal asthma. beta 2AR mRNA levels have been quantitated using the ribonuclease protection assay on RNA from peripheral lung obtained both at autopsy and thoracotomy from subjects with normal lungs as well as subjects with asthma or chronic obstructive pulmonary disease (COPD). Glucocorticosteroid and serum induction of beta 2AR mRNA in human epidermoid carcinoma A431 cells, which display a high abundance of beta 2AR receptors, was also examined to provide aliquots of RNA containing relatively high levels of beta 2AR mRNA for use as positive controls and internal standards. In A431 cells maintained after confluence in serum-free media for 72 h, maximal beta 2AR mRNA levels in response to 10% fetal bovine serum were 85% of maximal levels following serum plus 10 microM dexamethasone. Both autopsy and resected lung yielded undegraded RNA with a similar relative abundance of beta 2AR mRNA. Although geometric mean beta 2AR mRNA levels were similar in all three patient groups, relatively high levels were observed in resected lung in a subpopulation of subjects with mild or moderate asthma but not in autopsy lung from subjects with severe asthma. High levels of beta 2AR mRNA, presumably reflecting lung growth or asthma, were demonstrated in peripheral lung of a 4-yr-old child with asthma.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗
PubMed1992

Beta 2 adrenergic receptors in asthma: a current perspective.

The role of the beta 2-adrenergic receptor in both the pathogenesis and treatment of asthma has been a subject of intense speculation and investigation for 25 years. The physiological effects of endogenous circulating catecholamines and exogenous adrenergic agonists in the lung are mediated by the beta 2-adrenergic receptor, which is present on a variety of cell types. Documented effects of beta 2-adrenergic receptor activation in the human lung include smooth muscle relaxation, inhibition of acetylcholine release from cholinergic nerve terminals, stimulation of serous and mucous cell secretion, increases in ciliary beat frequency, promotion of water movement into the airway lumen by stimulation of ion secretion across the apical membrane of epithelial cells, increase in bronchial blood flow, reduction in venular permeability, and inhibition of mediator release from some, but not all, inflammatory cells. Beta 2-Adrenergic receptors are present in normal or increased numbers on asthmatic airway smooth muscle but are uncoupled in severe asthma, leading to functional hyporesponsiveness, probably due to the effects of inflammatory mediators. There is also evidence for dysfunction of beta 2-adrenergic receptors on circulating inflammatory cells following mediator release. However, dysfunction of the receptors on airway smooth muscle and inflammatory cells is unlikely to be of primary importance in the pathogenesis of asthma. There is increasing concern that regular beta 2-adrenergic receptor agonist use in the therapy of asthma is deleterious. Although a number of theories have been advanced to explain such an effect, none is well established and further research is urgently required.

Adrenergic beta-Agonists↗
PubMed1992

A comparison of beta-adrenergic receptors and in vitro relaxant responses to isoproterenol in asthmatic airway smooth muscle.

In previous reports, we have documented decreased in vitro airway smooth muscle responses to isoproterenol (ISO) in fresh postmortem trachea and bronchus from subjects with fatal asthma. One hypothesis to explain this finding is a decrease in beta-adrenergic receptor (beta AR) numbers on airway smooth muscle. We have now examined the autoradiographic distribution and density of beta AR using [125I]iodocyanopindolol on sections of airway smooth muscle adjacent to those studied functionally. The results have been compared with "normal" trachea and bronchi obtained from persons dying suddenly of nonpulmonary causes. In both trachea and bronchi, there was a 2.8-fold and 2.5-fold increase in specific grain counts, respectively, over smooth muscle from asthmatic airways (n = 6) compared with that determined in normal airways (n = 4, P less than 0.01, unpaired t test). The affinity of the beta AR for the agonist ISO, as determined by competitive binding experiments with increasing concentrations of (-)-ISO on tissue sections, was increased in asthmatic bronchi (IC50 = 80 +/- 13 nM; n = 3) compared with normal bronchi (IC50 = 562 +/- 144 nM; n = 4, P less than 0.05). We conclude that beta AR-mediated relaxant abnormalities in airway smooth muscle in fatal asthma cannot be explained by a decrease in receptor number and, surprisingly, beta AR expression is increased.

Asthma↗
PubMed1991

Abnormalities in airway smooth muscle in fatal asthma. A comparison between trachea and bronchus.

Tracheal smooth muscle from seven cases of fatal asthma demonstrated an increased contractile response to histamine, acetylcholine, and electrical stimulation of intrinsic cholinergic nerves; impaired relaxation to isoproterenol, and possibly theophylline, was also evident (1). Fourth generation bronchial spirals from the same patients were also studied, and these results were compared with those of the trachea and normal bronchi (n = 5). In contrast to trachea, contractile responses in asthmatic bronchi to acetylcholine, histamine, and cholinergic nerve stimulation were similar to those in control bronchi. The potency of isoprenaline (IC50) was reduced 9.4-fold (p less than 0.003), similar to trachea (4.5-fold), whereas theophylline responses were normal. The discrepant results obtained may reflect differences in the disease process, including rates of postmortem change, at the two anatomic sites.

Acetylcholine↗
PubMed1990

Abnormalities in airway smooth muscle in fatal asthma.

The characteristics of asthmatic airway smooth muscle are poorly described. Using standard organ bath techniques, the in vitro isometric contractile and relaxant responses of tracheal strips obtained from seven asthmatics (A) (mean age, 48 +/- 6 SEM yr) dying during severe asthma attacks outside hospital were studied 7.6 +/- 1.3 h after death. Drug therapy had varied, but it had always included inhaled beta 2-agonists. Control data (C) were obtained from 31 subjects (54 +/- 2 yr) studied 9.5 +/- 0.4 h after sudden nonrespiratory death. Cholinergic contractile and nonadrenergic noncholinergic inhibitory (NANCI) neural responses were studied with electrical field stimulation (EFS); histamine, isoproterenol (ISO), and theophylline (THEO) responses were studied using cumulative techniques. The maximal response (Tmax, g/g tissue) to histamine, cholinergic EFS (A = 61.3 +/- 13.2, C = 33.6 +/- 3.6, p less than 0.0001), (A = 70.3 +/- 11.8, C = 47.3 +/- 4.5, p = 0.041), and acetylcholine (ACh) (A = 101.9 +/- 17.4, C = 62.7 +/- 7.5, p = 0.012) was greater in the asthmatics but NANCI responses were similar. Cholinergic Tmax (EFS) as a percentage of Tmax (ACh), EC50 (histamine), and EF50 (EFS) were similar in the two groups. With tissues contracted to 60% of maximum with histamine, the concentrations of ISO (A = 60.3 nM, C = 12.7, p = 0.01) and THEO (A = 31.9 microM, C = 5.7, p = 0.041) to reduce tension by 50% (IC50) were greater in asthmatics.(ABSTRACT TRUNCATED AT 250 WORDS)

Acetylcholine↗
PubMed1989

Effects of adrenergic agonists and adenosine on cholinergic neurotransmission in human tracheal smooth muscle.

There is only limited information available on the prejunctional regulation of acetylcholine (ACh) release from cholinergic nerves in human airway smooth muscle. Stimulation of cholinergic nerves in fresh postmortem tracheal muscle strips with electrical field stimulation (EFS) causes reproducible contractions. We have studied the effect on contractile responses of: 1) The alpha 2-adrenoceptor agonist effect of noradrenaline (NA, 0.1-30 microM) and clonidine (10 nM-30 microM), in the presence of 1 microM propranolol and prazosin +/- idazoxan (0.1 microM); 2) The beta-adrenoceptor agonist effect of fenoterol (FEN) and isoprenaline (ISO, 1 nM-30 microM) +/- ICI 118,551 (10 nM), comparing EFS responses to comparable responses to exogenous ACh; 3) The A1 and A2 adenosine receptor agonists effects of L-PIA and NECA (1 nM-10 microM). NA caused a concentration-dependent depression of the cholinergic frequency-response curve. However responses at 5 Hz were not modified by the addition of idazoxan. Similarly clonidine did not reduce contractile responses. The concentrations of isoprenaline (56 nM) and fenoterol (165 nM) required to inhibit EFS (5 Hz) by 50% (IC50) were significantly less than those required to inhibit closely matched ACh responses to a comparable degree (ISO = 117 and FEN = 304 nM), and the maximum inhibition of EFS was greater. Following isoprenaline and the beta 2-antagonist ICI 118,551 the IC50's for EFS and ACh were not different. NECA and PIA had no effect on cholinergic EFS. We conclude that a prejunctional beta 2 receptor may be present on cholinergic nerves in post-mortem tracheal smooth muscle but no evidence for alpha 2-adrenoceptor or adenosine-receptor regulation was obtained.

Adenosine↗